Physician profile
Caroline E Carr
NPI 1356791461
$5,500.58
in general payments reported to CMS, 2019-2025
26 companies · $1,432 in 2025
The $1,432 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $410 · 2021: $341 · 2022: $950 · 2023: $169 · 2024: $1,660 · 2025: $1,432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,090 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.35 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,571.40 | 2019-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $415.15 | 2019-2025 | Dupixent |
| Genzyme Corporation | $386.45 | 2021-2025 | |
| Dermavant Sciences, INC. | $332.93 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $289.85 | 2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $285.26 | 2020-2025 | Jublia |
| Leo Pharma INC. | $281.16 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $236.53 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $221.28 | 2021-2025 | Nemluvio, Aklief |
| Ucb, INC. | $209.76 | 2022-2025 | Bimzelx |
| Misonix INC | $191.34 | 2020 | |
| Lilly USA, LLC | $154.27 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $116.00 | 2024-2025 | Otezla, Otezla |
| Pfizer INC. | $111.57 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $102.16 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $90.57 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $84.74 | 2025 | |
| Celgene Corporation | $83.83 | 2019 | |
| Janssen Scientific Affairs, LLC | $82.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.89 | 2025 | |
| Organon LLC | $59.31 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $42.18 | 2024 | Zoryve |
| Botanix Sb INC | $29.86 | 2025 | Sofdra |
| Stryker Corporation | $19.21 | 2020 | |
| Almirall LLC | $16.10 | 2025 | Seysara |
| Sanofi Pasteur INC. | $15.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.